BMY, has entered a new collaboration with Oxford BioTherapeutics to develop T-cell engager therapies for solid tumours. The ...

Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data ...

The former leaders of SpringWorks Therapeutics are back with a new biotech venture that is already buzzing from a $300 ...

Saqib Islam, chief executive Officer of newly launched Beeline Medicines. The pace of private financing in biopharma steps up ...

Wondering if Bristol-Myers Squibb at around US$58 a share still offers value, or if the easy gains are already behind it?

Bristol Myers Squibb (BMS) has added to its oncology pipeline through an exclusive global licensing agreement with Janux Therapeutics. This deal will see the pair co-develop a novel therapy for the ...

This partnership meshes with OBT’s hybrid partnership-pipeline strategy, which prioritises collaboration to extend its market impact.

Bristol-Myers Squibb (BMY) looks undervalued at 8.9x forward P/E; see growth catalysts, FDA/Phase 3 timelines, and a $68 ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...

There are pharmaceutical companies that can fit into a value investor's portfolio. Broadly speaking, these companies look ...